US20090220637A1 - Nutrition for obese patients - Google Patents

Nutrition for obese patients Download PDF

Info

Publication number
US20090220637A1
US20090220637A1 US12/064,686 US6468606A US2009220637A1 US 20090220637 A1 US20090220637 A1 US 20090220637A1 US 6468606 A US6468606 A US 6468606A US 2009220637 A1 US2009220637 A1 US 2009220637A1
Authority
US
United States
Prior art keywords
composition
vitamin
source
protein
total calories
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/064,686
Other languages
English (en)
Inventor
Claudia Roessle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Assigned to NESTEC S.A. reassignment NESTEC S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ROESSLE, CLAUDIA
Publication of US20090220637A1 publication Critical patent/US20090220637A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • This invention relates generally to compositions and methods for the treatment and nutritional support of patients. More specifically, this invention relates to the nutritional support of obese patients prior to, during and after hospitalisation for surgery, treatment of diseases or other disorders as well as during periods of convalescence.
  • BMI body mass index
  • obese patients have pre-existing chronic diseases related to their obesity such as impaired glycaemic control, diabetes mellitus, coronary artery disease, hypertension, respiratory abnormalities, hyperlipidaemia, degenerative joint disease, and hepatobiliary disease that are likely to complicate even routine hospital care.
  • obese patients are more likely than their non-obese counterparts to develop postoperative complications such as impaired wound-healing, nosocomial infections, respiratory complications, and delayed cardiac recuperation.
  • obesity BMI greater than 30
  • Obesity entails increased oxidative stress and, in many cases, sarcopenia.
  • hypocaloric enteral nutritional support by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml was at least as effective as eucaloric feeding in this group.
  • hypocaloric enteral nutritional support by which the authors meant feeding a composition with an energy density of at least 1.0 kcal/ml was at least as effective as eucaloric feeding in this group.
  • the nutrition offered post operatively in particular to be less than ideal.
  • this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises per litre at least 500 ⁇ g RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg ⁇ TE of Vitamin E, 4.0 mg zinc and 30 mg selenium and a protein source which provides at least 30% of the total calories of the composition wherein at least 30% by weight of the protein source is whey protein.
  • this invention provides the use of a protein source, a carbohydrate source, and a lipid source in the manufacture of a composition for the prevention or treatment of malnutrition in an obese patient wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight whey protein and provides at least 30% of the total calories of the composition.
  • this invention provides a nutritional composition for the prevention or treatment of malnutrition in an obese patient which composition has an energy density between 0.4 and 0.9 kcal/ml and comprises a protein source which provides at least 30% of the total calories of the composition, a carbohydrate source and a lipid source wherein at least 30% by weight of the protein source is whey protein.
  • this invention provides a method of preventing or treating malnutrition in an obese patient in need thereof by administering a therapeutic amount of a nutritional composition comprising a protein source wherein the composition has an energy density between 0.4 and 0.9 kcal/ml and the protein source comprises at least 30% by weight of whey protein and provides at least 30% of the total calories of the composition.
  • whey protein constitutes at least 50% of the protein source, more preferably from 60 to 85% of the protein source.
  • the composition may be a nutritional supplement, that is, nutritionally incomplete and intended to be consumed in addition to other foodstuffs or it may be nutritionally complete, including a carbohydrate source and a lipid source in addition to the protein source. It may be formulated as a ready to consume liquid for sip feeding or tube feeding, as a powdered composition which may be reconstituted with water prior to being fed orally or administered by tube feeding, as a semi-liquid food such as a spoonable dessert or in any other appropriate form e.g. bars, biscuits etc.
  • the carbohydrate source may provide 20 to 50% of the total calories of the composition and preferably from 25 to 45% of the total calories of the composition.
  • the lipid source may provide 10 to 40% of the total calories of the composition and preferably from 25 to 30% of the total calories of the composition.
  • the term “obese patient” means an individual who is obese i.e. with a BMI greater than 30 and who is undergoing or requires or is convalescing from therapy or surgery for a related or unrelated condition.
  • related conditions include conditions that are thought to be linked with overweight and obesity such as development of metabolic syndrome and Type II diabetes.
  • references to components of the composition being present in a specified number of grams per litre refer in the context of powdered compositions to the composition after re-constitution.
  • Whey protein comprises at least 30% of the protein source in the composition of the invention, preferably at least 50% and more preferably from 60 to 85% of the protein source.
  • Whey protein has fast gastric emptying and is associated with an increased satiety response so is suitable for a hypocaloric composition for obese patients. Further, it has been shown to stimulate insulin release in healthy subjects as well as those suffering from Type II diabetes and is thus a suitable protein source for individuals who may suffer from impaired glycaemic control. Whey protein has also been demonstrated to stimulate postprandial protein accretion; in particular in elderly subjects suggesting that protein losses can be limited by intake of whey protein. It is also a rich source of branched-chain amino acids which it is believed may be associated with the stimulation of protein synthesis.
  • whey protein is a rich source of cysteine which is a key constituent of glutathione, a major endogenous antioxidant. It has been shown that cysteine and glutathione are depleted in critically ill patients and that supplementation with cysteine can attenuate this depletion. Finally, whey protein is believed to have anti-inflammatory properties which may be of relevance in the treatment of conditions such as obesity which are thought to engender chronic low-level inflammation.
  • the whey protein may be intact or partially or extensively hydrolysed. Mixtures of intact and hydrolysed whey proteins may be used.
  • the balance of the protein source may be any suitable protein such as defatted milk protein, soy protein or casein, in each case either in the intact form or hydrolysed. Mixtures of the above proteins may also be used as may mixtures of intact and hydrolysed proteins. Free amino acids such as Leucine may also be added.
  • the lipid source if present preferably does not contribute more than 40% of the total calories of the composition since the use of endogenous lipid stores should be stimulated in obese patients. Nevertheless, essential fatty acid intake should be considered.
  • n-6 polyunsaturated fats should preferably be avoided where there is a risk of stress and inflammatory conditions.
  • the ratio of n6/n3 fatty acids should be between 2:1 and 6:1.
  • These requirements can, for example, be met by using a blend of canola oil, corn oil and high-oleic acid sunflower oil supplemented with a source rich in n3 PUFA such as fish oil if a higher n3 content is required.
  • the lipid source may also include medium chain triglycerides if required.
  • the nutritional composition of the present invention may contain a carbohydrate source.
  • the carbohydrate source should be slowly digested or metabolised independently of insulin, thus avoiding high post-prandial glycaemic peaks.
  • Suitable carbohydrate sources are modified starches such as modified potato or tapioca starch, dextrins such as tapioca dextrin, isomaltulose, trehalose, tagatose, fructose and polyols such as xylitol and sorbitol as well as mixtures thereof.
  • the composition may also contain minerals, micronutrients and trace elements in accordance with the recommendations of Government bodies such as the USRDA.
  • the composition contains elevated amounts of Vitamins A, C, and E, zinc and selenium, for example, per litre at least: 500 ⁇ g RE of Vitamin A, 70 mg of Vitamin C, 9.0 mg ⁇ TE of Vitamin E, 4.0 mg zinc and 30 mg selenium, more preferably per litre at least: 1000 ⁇ g RE of Vitamin A, 125 mg of Vitamin C, 15.0 mg ⁇ TE of Vitamin E, 10.0 mg zinc and 100 mg selenium.
  • the composition preferably also contains elevated amounts of iron, calcium, folate, Vitamin B12, Vitamin D and Vitamin K, for example, per litre at least 6 mg iron, 500 mg calcium, 160 mg folate, 2.0 ⁇ g Vitamin B12, 8 ⁇ g Vitamin D and 60 ⁇ g Vitamin K.
  • the composition may further contain a source of dietary fibre.
  • Dietary fibre passes through the small intestine undigested by enzymes and functions as a natural bulking agent and laxative. Dietary fibre may be soluble or insoluble and in general a blend of the two types is preferred. Suitable sources of dietary fibre include soy, oat and gum Arabic and mixtures thereof.
  • a particularly preferred fibre blend is a mixture of outer pea fibre (predominantly insoluble), inner pea fibre, acacia gum and short chain fructo-oligosaccharides (all soluble).
  • the fibre content is between 10 and 40 g/l.
  • the liquid mixture may then be cooled to about 60° C. to about 85° C.; for example by flash cooling.
  • the liquid mixture may then be homogenised; for example in two stages at about 7 MPa to about 40 MPa in the first stage and about 2 MPa to about 14 MPa in the second stage.
  • the homogenised mixture may then be further cooled and any heat sensitive components; such as vitamins and minerals may be added.
  • the pH and solids content of the homogenised mixture is conveniently standardised at this point.
  • the homogenised mixture is filled into suitable containers; preferably aseptically.
  • the composition may also be retorted in the container. Suitable apparatus for carrying out filling of this nature is commercially available.
  • the composition may be in the form of a ready to feed product having a solids content of about 10 to about 14% by weight or may be in the form of a concentrate; usually of solids content of about 20 to about 26% by weight.
  • a dispersion of defatted milk protein concentrate and tri-calcium-citrate in demineralised water is prepared.
  • the fat mix is warmed to 70° C. and mono-diglycerides are dissolved in the fat.
  • the fat mix is emulsified together with the protein dispersion using a colloidal mill.
  • the resulting coarse emulsion is homogenised at 200 bar/40 bar at ca 65° C.
  • the minerals, trace elements and vitamins are then added to the emulsion and its pH is adjusted to 6.8.
  • the resulting emulsion is UHT sterilised, flash-cooled to 70° C. and then aseptically homogenised.
  • the emulsion is cooled to about 10° C. and pumped to a sterile tank where it is mixed with the protein/carbohydrate phase After thorough mixing in the tank, the sterile composition is filled aseptically into the desired containers.
  • compositions have the following nutrient profiles (per 200 ml serving):
  • Example B Caloric Density 0.5 kcal/ml 0.75 kcal/ml Protein (g) 12 15 Carbohydrate (g) 6.8 11.25 Fat (g) 2.8 5 Dietary Fibre (g) 5.2 5.2 Vitamin A ( ⁇ g RE) 210 210 E Vitamin D ( ⁇ g) 2.6 2.6 Vitamin E (mg ⁇ TE) 3.2 4.5 E Vitamin K ( ⁇ g) 13.8 13.8 Vitamin C (mg) 26 26 Vitamin B1 (mg) 0.3 0.3 Vitamin B2 (mg) 0.36 0.36 Niacin (mg) 3.0 3.0 Vitamin B6 (mg) 0.42 0.42 Folic Acid ( ⁇ g) 60 60 Pantothenic Acid (mg) 1.2 1.2 Vitamin B12 ( ⁇ g) 0.7 1.0 Biotin ( ⁇ g) 7.5 12 Calcium (mg) 240 240 Magnesium (mg) 40 40 Zinc (mg) 2.4 2.4 Iron (mg) 2.0 2.0 Copper (mg) 0.24 0.24 Mangan ( ⁇ g)
  • liquid tube feeding compositions according to the present invention are given below.
  • the compositions are given by way of illustration only.
  • compositions include the following ingredients: protein: hydrolysed whey protein (50% by weight of total protein), potassium caseinate; soy protein isolate; carbohydrate: modified tapioca and corn starch; fat: about 50% canola oil, about 20% corn oil, about 30% high-oleic sunflower oil, n6:n3 ratio about 5; fibre (inner pea fibre, outer pea fibre, acacia gum and fructo-oligosaccharides); water; vitamin A; vitamin C vitamin D; vitamin E; vitamin K; vitamin B 1 ; Vitamin B 2 ; vitamin B 6 ; niacin; folic acid; pantothenic acid; vitamin B 12 ; biotin; calcium; magnesium; zinc; iron; copper; manganese; iodine; sodium; potassium; chloride; chromium; molybdenum; fluoride and selenium.
  • protein hydrolysed whey protein (50% by weight of total protein), potassium caseinate
  • carbohydrate modified tapioca and corn starch
  • fat about 50% can
  • compositions have the following nutrient profiles (per 1500 ml):
  • Example D Caloric Density 0.5 kcal/ml 0.75 kcal/ml Protein (g) 84 100 Carbohydrate (g) 47 124 Fat (g) 25 37.5 Dietary Fibre (g) 22.5 22.5 Vitamin A ( ⁇ g RE) 1950 1950 Vitamin D ( ⁇ g) 22.5 22.5 Vitamin E (mg ⁇ TE) 30 30 Vitamin K ( ⁇ g) 124.5 124.5 Vitamin C (mg) 225 225 Vitamin B1 (mg) 2.7 2.7 Vitamin B2 (mg) 3.0 3.0 Niacin (mg) 27 27 Vitamin B6 (mg) 3.9 3.9 Folic Acid ( ⁇ g) 540 540 g Pantothenic Acid (mg) 11.25 11.25 Vitamin B 12 ( ⁇ g) 6.75 6.75 Biotin ( ⁇ g) 67.5 67.5 Calcium (mg) 1350 1350 1350

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US12/064,686 2005-08-26 2006-08-22 Nutrition for obese patients Abandoned US20090220637A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP05018626.1 2005-08-26
EP05018626 2005-08-26
EP05110556.7 2005-11-09
EP05110556 2005-11-09
PCT/EP2006/065562 WO2007042341A1 (fr) 2005-08-26 2006-08-22 Nutrition pour les patients obeses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/065562 A-371-Of-International WO2007042341A1 (fr) 2005-08-26 2006-08-22 Nutrition pour les patients obeses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/053,192 Continuation US9549569B2 (en) 2005-08-26 2013-10-14 Nutrition for obese patients

Publications (1)

Publication Number Publication Date
US20090220637A1 true US20090220637A1 (en) 2009-09-03

Family

ID=37735137

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/064,686 Abandoned US20090220637A1 (en) 2005-08-26 2006-08-22 Nutrition for obese patients
US14/053,192 Expired - Fee Related US9549569B2 (en) 2005-08-26 2013-10-14 Nutrition for obese patients

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/053,192 Expired - Fee Related US9549569B2 (en) 2005-08-26 2013-10-14 Nutrition for obese patients

Country Status (13)

Country Link
US (2) US20090220637A1 (fr)
EP (1) EP1921928A1 (fr)
JP (2) JP2009506012A (fr)
CN (1) CN101247735B (fr)
AU (1) AU2006301389B9 (fr)
BR (1) BRPI0615396A2 (fr)
CA (1) CA2620366C (fr)
IL (1) IL188847A0 (fr)
MX (1) MX2008002701A (fr)
MY (1) MY145662A (fr)
RU (1) RU2385647C2 (fr)
TW (1) TW200740379A (fr)
WO (1) WO2007042341A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070142469A1 (en) * 2005-12-19 2007-06-21 Thomas Debra L Method of using beta-hydroxy-beta-methylbutyrate
US20100247505A1 (en) * 2007-10-25 2010-09-30 Nutri Co., Ltd. Composition for Reducing the Level of Glucose, Malondialdehyde-Modified LDL, Homocysteine and/or C-Reactive Protein in Blood
US20110305799A1 (en) * 2010-06-10 2011-12-15 Abbott Laboratories Substantially clear nutritional liquids comprising calcium hmb and soluble protein
ITRM20100403A1 (it) * 2010-07-20 2012-01-21 Antonio Picarelli Sussidio dietetico per il trattamento dell'obesita' e di altre condizioni patologiche quali la resistenza insulinica ed il diabete mellito tipo 2
US8609725B2 (en) 2004-03-26 2013-12-17 Abbott Laboratories Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate
WO2014200332A1 (fr) * 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
US9241508B2 (en) 2010-01-29 2016-01-26 Abbott Laboratories Nutritional emulsions comprising calcium HMB
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
CN113331305A (zh) * 2021-05-10 2021-09-03 江苏雅博动物健康科技有限责任公司 一种含膳食纤维的宠物用代餐粉

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102131405B (zh) * 2008-06-19 2014-06-11 纽迪希亚公司 用于减肥手术患者的液体营养组合物
EP2670262B2 (fr) 2011-02-02 2025-10-15 Société des Produits Nestlé S.A. Compositions nutritionnelles riches en protéine et d'utilisation de celles-ci
GB201210100D0 (en) * 2012-06-08 2012-07-25 Whey Forward Health Ind Ltd Nutraceutical pharmaceutical composition
CN105992520A (zh) * 2013-12-19 2016-10-05 雅培公司 包含水解蛋白质的营养组合物
CA3001091A1 (fr) * 2015-11-20 2017-05-26 Nestec S.A. Methodes utilisant une proteine lactoserique pour ameliorer ou maintenir une qualite musculaire
ES3021188T3 (en) * 2015-11-30 2025-05-26 Fresenius Kabi Deutschland Gmbh High protein enteral tube feed for icu patients
CN105901701A (zh) * 2016-04-18 2016-08-31 邱小文 一种代谢手术营养剂
CN106880042A (zh) * 2017-01-18 2017-06-23 恩施硒域传奇健康管理有限公司 一种适用于肥胖、减脂手术患者恢复期的全营养配方食品
US11197917B2 (en) 2017-12-01 2021-12-14 ByHeart, Inc. Formulations for nutritional support in subjects in need thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
US20020142025A1 (en) * 1997-07-14 2002-10-03 Robert Johan Joseph Hageman Nutritional composition containing methionine
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050002988A1 (en) * 2001-09-07 2005-01-06 Kenji Mizumoto Nutritional composition for controlling blood sugar level
US20050147665A1 (en) * 1999-07-14 2005-07-07 Laxdale Limited Pharmaceutical and nutritional compositions
US20050233045A1 (en) * 2003-09-03 2005-10-20 Aldred Deborah L Satiety enhancing food compositions
US20060159724A1 (en) * 2000-08-08 2006-07-20 Bell Stacey J Nutritional supplement for the management of weight

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3487079B2 (ja) * 1996-06-17 2004-01-13 不二製油株式会社 抗肥満食品
AU9433698A (en) * 1998-10-09 2000-05-01 Sanacare Aps Diet food
JP2001120227A (ja) * 1999-10-29 2001-05-08 We'll Corporation:Kk ダイエット食品
DE10057290B4 (de) * 2000-11-17 2004-01-08 Fresenius Kabi Deutschland Gmbh Enteral zu verabreichendes Supplement zur parenteralen Ernährung oder partiellen enteralen/oralen Ernährung bei kritisch Kranken, chronisch Kranken und Mangelernährten
EP1302111A1 (fr) * 2001-10-09 2003-04-16 Bariatrix Products International, Inc. Compositions diététiques et procédé
MXPA05012702A (es) * 2003-05-28 2006-02-08 Unilever Nv Productos alimenticios que incrementan la saciedad.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142025A1 (en) * 1997-07-14 2002-10-03 Robert Johan Joseph Hageman Nutritional composition containing methionine
US5968896A (en) * 1998-01-16 1999-10-19 Beth Israel Deaconess Medical Center Nutritional supplement for preoperative feeding
US20050147665A1 (en) * 1999-07-14 2005-07-07 Laxdale Limited Pharmaceutical and nutritional compositions
US20060159724A1 (en) * 2000-08-08 2006-07-20 Bell Stacey J Nutritional supplement for the management of weight
US20050002988A1 (en) * 2001-09-07 2005-01-06 Kenji Mizumoto Nutritional composition for controlling blood sugar level
US20040258826A1 (en) * 2001-12-20 2004-12-23 Navarro Y Koren Peter Antonio Matrix-forming composition containing pectin
US20050233045A1 (en) * 2003-09-03 2005-10-20 Aldred Deborah L Satiety enhancing food compositions

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8778994B2 (en) 2004-03-26 2014-07-15 Abbott Laboratories Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting
US8785496B2 (en) 2004-03-26 2014-07-22 Abbott Laboratories Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting
US8785495B2 (en) 2004-03-26 2014-07-22 Abbott Laboratories Compositions including beta-hydroxy-beta-methylbutyrate
US8778993B2 (en) 2004-03-26 2014-07-15 Abbott Laboratories Method of using β-hydroxy-β-methylbutyrate for the treatment of disease conditions
US8609725B2 (en) 2004-03-26 2013-12-17 Abbott Laboratories Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate
US8796333B2 (en) 2005-12-19 2014-08-05 Abbott Laboratories Method of using β-hydroxy-β-methylbutyrate to treat a condition
US8778992B2 (en) 2005-12-19 2014-07-15 Abbott Laboratories Method of using beta-hydroxy-beta-methylbutyrate to treat allergies and asthma
US20070142469A1 (en) * 2005-12-19 2007-06-21 Thomas Debra L Method of using beta-hydroxy-beta-methylbutyrate
US20100247505A1 (en) * 2007-10-25 2010-09-30 Nutri Co., Ltd. Composition for Reducing the Level of Glucose, Malondialdehyde-Modified LDL, Homocysteine and/or C-Reactive Protein in Blood
US10383893B2 (en) 2007-10-25 2019-08-20 Nutri Co., Ltd. Composition for reducing the level of glucose, malondialdehyde-modified LDL, homocysteine and/or C-reactive protein in blood
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
US8916217B2 (en) 2010-01-29 2014-12-23 Abbott Laboratories Aseptically packaged nutritional liquids comprising HMB
US9241508B2 (en) 2010-01-29 2016-01-26 Abbott Laboratories Nutritional emulsions comprising calcium HMB
US20110305799A1 (en) * 2010-06-10 2011-12-15 Abbott Laboratories Substantially clear nutritional liquids comprising calcium hmb and soluble protein
US9521859B2 (en) * 2010-06-10 2016-12-20 Normanella T. Dewille Substantially clear nutritional liquids comprising calcium HMB and soluble protein
US10045999B2 (en) 2010-07-07 2018-08-14 N. V. Nutricia Nutritional composition for the stimulation of muscle protein synthesis
ITRM20100403A1 (it) * 2010-07-20 2012-01-21 Antonio Picarelli Sussidio dietetico per il trattamento dell'obesita' e di altre condizioni patologiche quali la resistenza insulinica ed il diabete mellito tipo 2
US20160128372A1 (en) * 2013-06-10 2016-05-12 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
US9961932B2 (en) * 2013-06-10 2018-05-08 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
AU2013392167B2 (en) * 2013-06-10 2017-04-27 N.V. Nutricia Muscle preservation in overweight or obese adult during weight loss program
WO2014200332A1 (fr) * 2013-06-10 2014-12-18 N.V. Nutricia Conservation des muscles chez des adultes en surpoids ou obèses pendant un programme de perte de poids
CN113331305A (zh) * 2021-05-10 2021-09-03 江苏雅博动物健康科技有限责任公司 一种含膳食纤维的宠物用代餐粉

Also Published As

Publication number Publication date
CA2620366C (fr) 2014-04-01
CN101247735B (zh) 2012-02-01
AU2006301389A1 (en) 2007-04-19
IL188847A0 (en) 2008-04-13
AU2006301389B2 (en) 2011-04-28
RU2385647C2 (ru) 2010-04-10
WO2007042341A1 (fr) 2007-04-19
JP2009506012A (ja) 2009-02-12
RU2008107342A (ru) 2009-09-10
BRPI0615396A2 (pt) 2011-05-17
MY145662A (en) 2012-03-15
MX2008002701A (es) 2008-03-18
US20140051627A1 (en) 2014-02-20
US9549569B2 (en) 2017-01-24
AU2006301389B9 (en) 2011-05-12
CN101247735A (zh) 2008-08-20
EP1921928A1 (fr) 2008-05-21
TW200740379A (en) 2007-11-01
CA2620366A1 (fr) 2007-04-19
JP2013199471A (ja) 2013-10-03

Similar Documents

Publication Publication Date Title
US9549569B2 (en) Nutrition for obese patients
US6592863B2 (en) Nutritional composition
US8372442B2 (en) Liquid nutritional composition for bariatric surgery patients
US20090075862A1 (en) Method for providing glutamine
BRPI0914793B1 (pt) composição nutricional, e, uso de uma composição nutricional
EP0898900A2 (fr) Composition et procédé de nutrition pour diabétiques
JP2003530411A (ja) 遊離アミノ酸含有組成物
BR112019009757B1 (pt) Pufa, vitamina e, vitamina d e os aminoácidos ligados às proteínas glicina, arginina e triptofano, seu uso na fabricação de uma composição nutricional para tratar sarcopenia e/ou fraqueza e composição nutricional
TW202317083A (zh) 經腸營養製劑
US20160317600A1 (en) Nutritional composition comprising hydrolyzed protein
EP3383202B1 (fr) Alimentation entérale par sonde à protéine élevée pour des patients d'unité de soins intensifs
MXPA98005035A (en) Composition and method for providing nutrition to diabeti
EP2299850A2 (fr) Composition nutritionnelle liquide destinée à des patients ayant subi une chirurgie bariatrique
HK1039729B (en) Method for providing glutamine

Legal Events

Date Code Title Description
AS Assignment

Owner name: NESTEC S.A., SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROESSLE, CLAUDIA;REEL/FRAME:021168/0459

Effective date: 20080526

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION